Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To investigate clinical features and potential mechanisms involving α-synuclein oligomer and inflammation in patients with Parkinson disease (PD) and probable REM sleep behavior disorder (PRBD). METHODS: We used the REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) to evaluate patients with PD and classified each as PRBD or not probable (NPRBD). Data collection included demographic information and evaluation of clinical symptoms using a series of rating scales. We tested for α-synuclein oligomer and inflammatory factors in CSF and serum. Data analyses included comparisons between PRBD and NPRBD groups and correlation analyses among RBDSQ score and levels of the above factors. RESULTS: The frequency of PRBD in patients with PD was 30.67%. The PRBD group had longer disease duration, more advanced disease stage, more severe motor symptoms, and other more severe nonmotor symptoms, including depression, anxiety, and fatigue. Levels of α-synuclein oligomer in CSF and serum in the PRBD group were elevated compared with NPRBD and control groups. RBDSQ score was increased with the elevated α-synuclein oligomer level in CSF, interleukin 1β and nitric oxide levels in CSF, and prostaglandin E2 level in serum in the PD group. The level of α-synuclein oligomer in CSF was enhanced with the deterioration of motor symptoms, and the elevated levels of interleukin 1β, nitric oxide, and tumor necrosis factor α in CSF in the PRBD group. CONCLUSIONS: PRBD is common in patients with PD, especially those with longer disease duration and more severe motor and nonmotor symptoms. Elevated α-synuclein levels in CSF and serum may be correlated with PRBD through inflammation in central and peripheral nervous systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
Self-citationIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“Furthermore, a PET imaging study in patients with PD revealed widespread microglial activation outside of the nigrostriatal circuit.(31) Excessive inflammation beyond the nigrostriatal pathway may be caused by widespread PD pathology, which evokes subsequent extranigral neuronal damage.”
BackgroundSystemic infections and inflammation affect chronic neurodegeneration
Perry, V. H., Cunningham, C., & Holmes, C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2015 · Cited by 1,027 · cited 1×
“In neurodegenerative diseases such as PD, systemic inflammation has been related to brain inflammation and neurodegeneration.(28) Systemic IL-1b can potentiate microglial activation in the SN and accelerated neurodegeneration in 6-hydroxydopamine– treated rats.”
BackgroundMogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
Cytokines and cognition–the case for a head-to-toe inflammatory paradigm.
Wilson, C. J., Finch, C. E., & Cohen, H. J. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50619.x · Cited by 637
Nitric oxide synthase and neuronal vulnerability in parkinson's disease
Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., & Hirsch, E. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00578-1 · Cited by 595
El-Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., Curran, M. D., Court, J. A., Mann, D. M. A., Ikeda, S.-I., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0098fje · Cited by 590
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · cited 1×
“Systemic IL-1b can potentiate microglial activation in the SN and accelerated neurodegeneration in 6-hydroxydopamine– treated rats.(29) In this study, IL-1b and TNF-a levels in serum in patients with PD were dramatically increased compared with those in the control group.”
Result
Cited by
Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2742 · Cited by 554
Self-citationBiomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Fan, Z., Pan, Y.-T., Zhang, Z.-Y., Yang, H., Yu, S.-Y., Zheng, Y., Ma, J.-H., & Wang, X.-M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1670-6 · Cited by 228
“Although a number of studies showed associations between IL-1β concentrations and PD, those results were inconsistent between studies [9, 12, 31].”
ResultSelf-citationGenetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
“Elevated serum levels of TNF (52, 53), IL-1β (52, 54, 55), and IL-6 (52–54) have been observed in PD patients as reviewed in Qin et al.”
BackgroundEvidence for immune system alterations in peripheral biological fluids in Parkinson’s disease
Bartl, M., Xylaki, M., Bähr, M., Weber, S., Trenkwalder, C., & Mollenhauer, B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105744 · Cited by 33
Metadata
- Authors
- Hu, Y., Yu, S.-Y., Zuo, L.-J., Cao, C.-J., Wang, F., Chen, Z.-J., Du, Y., Lian, T.-H., Wang, Y.-J., Chan, P., Chen, S.-D., Wang, X.-M., & Zhang, W.
- Venue
- Neurology
- Published
- 2015-03-03
- Volume
- 84
- Issue
- 9
- Pages
- 888-894
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1965400322
- Cited by
- 99
- References
- 13
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation. https://app.cochat.ai/papers/10.1212/wnl.0000000000001308
- The paper
- Hu, Y., Yu, S.-Y., Zuo, L.-J., Cao, C.-J., Wang, F., Chen, Z.-J., Du, Y., Lian, T.-H., Wang, Y.-J., Chan, P., Chen, S.-D., Wang, X.-M., & Zhang, W. (2015). Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation. Neurology. https://doi.org/10.1212/wnl.0000000000001308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.